Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report 2024

This Gonadotropin-Releasing Hormone (GnRH) Agonist market report covers industry characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to increasing awareness and diagnosis of hormonal disorders, a rising prevalence of hormone-related diseases, a growing incidence of prostate cancer, heightened awareness about hormone therapy, and a greater demand for long-term safety and efficacy.

The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.6 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to increased awareness and early diagnosis, rising healthcare expenditure, growing use of GnRH agonists in fertility treatments, a heightened demand for personalized medicine, and more research funding and grants. Major trends expected include advancements in drug delivery systems, progress in oncology and reproductive medicine, a growing demand for hormone therapy options, increased research and development efforts, and the rise of long-acting formulations.

The rising prevalence of hormone-related diseases is anticipated to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders are medical conditions resulting from imbalances or malfunctions in the endocrine system, which regulates hormone production. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. Factors such as environmental influences, obesity, metabolic syndrome, genetics, and an aging population contribute to the increasing incidence of these diseases. GnRH agonists help manage hormone levels and offer a targeted approach to treating issues associated with hormonal imbalances and hormone-dependent conditions. For instance, a report by the Centers for Disease Control and Prevention (CDC) in June 2024 revealed that in 2021, there were 236,659 new cases of prostate cancer in the U.S., with 33,363 deaths from the disease in 2022. Thus, the growing prevalence of hormone-related diseases is fueling the demand for GnRH agonists.

Companies in the GnRH agonist market are focusing on developing advanced androgen deprivation therapy (ADT) drugs to improve treatment efficacy and precision for hormone-sensitive cancers. ADT drugs, including GnRH analogs, work by reducing or eliminating androgen levels, thereby slowing or stopping the growth of hormone-sensitive cancers. For example, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, introduced Relugolix under the brand name Rexigo. This is India's first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. Relugolix, a globally recognized active ingredient, provides rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable treatments for advanced prostate cancer in India, marking a significant advancement in prostate cancer care by offering a safe, effective, and convenient treatment option for patients and healthcare providers.

In February 2022, Debiopharm, a Switzerland-based manufacturer of GnRH agonists, partnered with Aspen Holdings to launch Trelstar in South Africa. This collaboration aims to introduce Trelstar as a treatment for locally advanced and metastatic hormone-dependent prostate cancer. The partnership is set to deliver a high-quality oncology product, significantly enhancing prostate cancer treatment in the region and improving the overall treatment landscape for affected patients. Aspen Holdings, based in South Africa, provides specialty and generic pharmaceuticals.

Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.

North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2023. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gonadotropin-releasing hormone (GnRH) agonists are synthetic drugs that mimic the action of natural GnRH, stimulating the pituitary gland to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These agents are employed to manage hormonal imbalances by regulating hormone levels and are particularly valuable in fertility treatments, where they help control and prevent premature ovulation during procedures such as in vitro fertilization.

The main types of GnRH agonists include leuprorelin, goserelin, taltirelin, histrelin, and others. Leuprorelin, a synthetic hormone, is used to treat prostate cancer, endometriosis, and uterine fibroids by decreasing hormone production. It is administered via monthly or quarterly injections and comes in various formulations, such as injectables, implants, oral tablets, and nasal sprays. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online pharmacies. Applications of leuprorelin encompass prostate cancer, breast cancer, endometriosis, uterine fibroids, precocious puberty, and fertility treatments, with end users including hospitals, specialty clinics, ambulatory surgical centers (ASCs), and other medical facilities.

The gonadotropin-releasing hormone (GnRH) agonists market research report is one of a series of new reports that provides gonadotropin-releasing hormone (GnRH) agonists market statistics, including the gonadotropin-releasing hormone (GnRH) agonists industry global market size, regional shares, competitors with the gonadotropin-releasing hormone (GnRH) agonists market share, detailed gonadotropin-releasing hormone (GnRH) agonists market segments, market trends, and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) agonists industry. These gonadotropin-releasing hormone (GnRH) agonists market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gonadotropin-releasing hormone (GnRH) agonists market consists of sales of triptorelin, buserelin, and nafarelin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.